Chambergo-Michilot Diego, De la Cruz-Ku Gabriel, Sterner Rosalie M, Brañez-Condorena Ana, Guerra-Canchari Pedro, Stulak John
Universidad Científica del Sur, Lima, Perú.
Department of Cardiology Research, Torres de Salud National Research Center, Lima, Perú.
J Cardiovasc Thorac Res. 2023;15(1):1-8. doi: 10.34172/jcvtr.2023.30531. Epub 2023 Mar 16.
Primary cardiac angiosarcomas (PCA) are highly aggressive malignant heart tumors. Previous reports have shown a poor prognosis regardless of management, and no consensus or guidelines exist. It is necessary to clarify this information since patients with PCA have a short survival. Therefore, we aimed to systematically review clinical manifestations, management, and outcomes. We systematically searched in PubMed, Scopus, Web of Science, and EMBASE. We intended to include cross-sectional studies, case-control studies, cohort studies, and case series that reported clinical characteristics, management, and outcomes of patients with PCA. As a methodological approach, we used the Joanna Briggs Institute Critical Appraisal Checklist for Case Series and the Newcastle-Ottawa Scale for cohorts. We included six studies (five case series, one cohort). The mean/median age ranged from 39 to 48.9 years. Male sex was predominant. The most frequent manifestations were dyspnea (range: 50%-80%), pericardial effusion (29% & 56%), and chest pain (10%-39%). The mean tumor size ranged from 5.8 to 7.2 cm, with the majority of these localized in the right atrium (70-100%). The most common locations of metastasis were the lung (20%-55.6%), liver (10%-22.2%), and bone (10%-20%). Resection (22.9%-94%), and chemotherapy as neoadjuvant or adjuvant (30%-100%) were the most commonly used methods of treatment. Mortality ranged from 64.7% to 100%. PCA often presents late in its course and usually results in poor prognosis. We strongly recommend performing multi-institutional prospective cohorts to better study disease course and treatments to develop consensus, algorithms, and guidelines for this type of sarcoma.
原发性心脏血管肉瘤(PCA)是极具侵袭性的恶性心脏肿瘤。既往报告显示,无论采取何种治疗方式,其预后均较差,且尚无共识或指南。鉴于PCA患者生存期短,有必要阐明相关信息。因此,我们旨在对临床表现、治疗及预后进行系统评价。我们在PubMed、Scopus、Web of Science和EMBASE中进行了系统检索。我们纳入了报告PCA患者临床特征、治疗及预后的横断面研究、病例对照研究、队列研究和病例系列。作为一种方法学手段,我们使用了乔安娜·布里格斯研究所病例系列关键评价清单和队列研究的纽卡斯尔-渥太华量表。我们纳入了6项研究(5个病例系列,1个队列)。平均/中位年龄在39至48.9岁之间。男性居多。最常见的表现为呼吸困难(范围:50%-80%)、心包积液(29%和56%)和胸痛(10%-39%)。平均肿瘤大小在5.8至7.2厘米之间,其中大多数位于右心房(70%-100%)。最常见的转移部位是肺(20%-55.6%)、肝(10%-22.2%)和骨(10%-20%)。手术切除(22.9%-94%)以及新辅助或辅助化疗(30%-100%)是最常用的治疗方法。死亡率在64.7%至100%之间。PCA通常在病程晚期出现,预后通常较差。我们强烈建议开展多机构前瞻性队列研究,以更好地研究疾病进程和治疗方法,从而为此类肉瘤制定共识、算法和指南。